The emerging and evolving COVID-19 pandemic has created a global public health emergency. There is an urgent need to understand the underlying determinants of the outcome of COVID-19 and how this translates to individuals who are treated with immunomodulating medications. This information will be vital for informing assessments of risk of COVID-19 in individuals who are treated with systemic immunomodulation medication and for guiding clinical decision making around their treatments.
Atopic dermatitis (AD) is a common chronic inflammatory disease, with a lifetime prevalence of 15–30% in children and 2–10% in adults. Patients with moderate-to-severe AD are often treated with long-term systemic immunomodulating therapy. The impact of these immunomodulating medications on COVID-19 outcomes is currently unknown.
By collecting worldwide observational data on cases of COVID-19 in AD patients treated with and without systemic immunomodulating therapy, the SECURE-AD registry will enable description of the impact of COVID-19 on these patients and how factors such as age, comorbidities, and AD systemic immunomodulating treatments impact COVID-19 outcomes. Through broadscale participation and collaboration the data collected through the SECURE-AD registry will benefit the entire AD patient population and international clinical community.
SECURE-AD is closely aligned with recently established partner databases for outcomes to COVID-19 in other immune-mediated inflammatory diseases (such as www.covidibd.org, www.psoprotect.org and www.rheum-covid.org). We will continue to collaborate closely with these research teams in order to facilitate valuable cross-disease analyses.
You can find more information on the SECURE-Derm website.
APH contact persons: Angela Bosma, Annelie Musters, Phyllis Spuls
Contact: a.l.bosma@amsterdamumc.nl, a.h.musters@amsterdamumc.nl, ph.i.spuls@amsterdamumc.nl